Genfit, the SBF 120 laggard, plunges 12% after its Q3 results

Iqirvo royalties sharply up, but revenue declining

The Genfit share falls 12.06% to €10.06, placing it among the biggest decliners in the SBF 120, which itself drops 1.66%.

After a gain of nearly 9% over one month, the stock is trading at its 200-day moving average (MM200) of €10.10, and it has fallen below its 50-day moving average (MM50) of €10.58. The session follows the publication of the third-quarter financial information on November 5.

Over nine months, royalties paid by Ipsen on Iqirvo sales rise 188% to €36.3 million.

Total revenue nonetheless declines to €36.4 million, compared with €39.2 million a year earlier, due to the absence of a milestone payment booked in 2026, whereas 2025 included €26.6 million. Cash stands at €95.6 million as of September 30, compared with €113.8 million at the end of June.

Portzamparc raises its target to €23 while the stock trades at €10.06

In this context, Portzamparc published a price target of €23 today, up from €22.40 previously, with a buy rating from analysts. This target is more than 130% above the day's price. The company considers its cash sufficient to finance its activities beyond the end of 2028.

At the time of the November 5 publication, it also anticipated the possible receipt of a new commercial milestone payment, and the stock remains up 185.8% over one year.

The market, for its part, is experiencing a risk-averse session: the CAC 40 loses 1.65% following the Wall Street correction and the drop in technology stocks in Asia. The support at €7.83 and the resistance at €11.46 now frame the stock.